References in periodicals archive ?
That test was designed to see if MGDF could be used to increase platelet counts in blood donors.
Analysts had expected MGDF to generate annual sales of about $200 million.
program, Amgen is reviewing safety data from all MGDF studies.
than 400 patients given MGDF except for two cases of potentially
The success of MGDF, if confirmed in further trials, would mean the end of a decadelong search for a way to stimulate a patient's own production of platelets, said Gasson.
During the Phase I/II randomized and double-blinded clinical trial, investigators at Emory, UCLA and Duke University evaluated the tolerance and effect on platelets of MGDF in persons with advanced (stage III or IV) non-small-cell lung cancer.
At the same time, orally active TER199 offers the opportunity to provide the possible benefits of MGDF and TPO for platelet growth and the treatment of thrombocytopenia.
The clinical trials are designed to evaluate the safety and efficacy of MGDF in reducing the severity and duration of thrombocytopenia (too few platelets) when administered to cancer patients following treatment with chemotherapy drugs which suppress blood cell formation in the bone marrow.
Medical browser ?
Full browser ?